Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 12, 2018 | June 14, 2018 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | March 03, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2028-06-11 | Direct | 52,500 |
Reported balance
After 2018-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 52,500 · Balance 52,500 F1: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
KIORA PHARMACEUTICALS INC
Report date March 03, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.83 · Expires 2033-03-03 | Direct | 8,000 |
Reported balance
After 2023-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-03 · Grant · Acquired 8,000 · Balance 8,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2023 Filed Mar 7, 2023 20:13 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000029 · wf-form4_167823799654732.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-03-03 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:05 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011496 · tm225348d8_4.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:52 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001104659-21-011847 · tm215262-5_4seq1.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2031-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:31 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001104659-20-022845 · tm209305-5_4.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2030-02-14 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:39 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001144204-19-005051 · tv512449_form4.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 16:55 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038186 · tv498477_4.xml · nonDerivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,229 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to all of the shares on July 10, 2019. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:20 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 52,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001485003-18-000092 · wf-form4_152900761425185.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:18 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033620 · v469451_4.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:41 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Exercise / conversionStock Option (right to buy) · Derivative | 17,570 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001144204-17-031102 · v468441_4.xml · derivative · entry 2 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,570 shares Expires 2017-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable immediately at the time of grant. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 19:41 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | Exercise / conversionCommon Stock | 17,570 | $0.65 | $11,420.50 |
DisclosureSEC source: 0001144204-17-031102 · v468441_4.xml · nonDerivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:47 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantStock Option · Derivative | 8,072 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001485003-17-000070 · wf-form4_149557245721975.xml · derivative · entry 1 CHANEY PAUL G · CIK 0001277477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,072 Underlying: Common Stock · 8,072 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.